Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
<p>Abstract</p> <p>Background</p> <p>The once-weekly (QW) formulation of the glucagon-like peptide-1 receptor agonist exenatide has been demonstrated to improve A1C, fasting plasma glucose (FPG), body weight, serum lipid profiles, and blood pressure in patients with typ...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-04-01
|
| Series: | BMC Endocrine Disorders |
| Online Access: | http://www.biomedcentral.com/1472-6823/11/9 |